Plain-English translation of NCT05553236 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial, called TS ELiOT, is testing whether a newer genetic test (called next-generation sequencing) can help doctors treat drug-resistant tuberculosis more effectively. Right now, doctors use standard tests to figure out which medicines will work against a patient's tuberculosis bacteria. This study is comparing whether adding the genetic sequencing test gives doctors better information to choose the right treatment and helps patients get well faster.
Drug-resistant tuberculosis is a serious form of the disease that doesn't respond to common tuberculosis medicines. Doctors need better ways to quickly figure out which drugs will actually work for each patient so they can start the right treatment sooner and improve outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive either the standard tuberculosis testing plus genetic sequencing, or the standard testing alone — depending on which group you're assigned to. Your doctors will use these test results to guide your tuberculosis treatment plan. The study will follow your progress over time to see whether the genetic sequencing helped your doctors choose better medicines and improved your outcomes.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
South Africa
Sponsor
University of California, San Francisco
Collaborators
University of Stellenbosch, National Health Laboratory Service (NHLS), South Africa
Enrollment target
~2,500 participants
Started
August 2024
Primary completion
January 2027
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
John Z Metcalfe, MD, PhD
University of California, San Francisco
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.